Interestingly, now that they have been removed from that list, a different access-related challenge may occur in that if compounding pharmacies are unable to supply these drugs (due to them no longer being on the FDA shortage list), individuals who obtained their medication via such methods may experience higher overall costs
It also activates p38 MARK, ERK1/2 cascade, and JNK cascade, which promotes apoptosis and inflammation (Potilinski et al., 2020)
If you change jobs mid-year, you may lose access to your FSA funds
Some drugs dont mix well with GLP-1 antagonists
doi:10.1038/s41574-022-00716-0 21
Biological concern for PDAC based on preclinical studies In 2005, exenatide, the first GLP-1RA was marketed as treatment for T2D